Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-13
DOI
10.1038/s41571-020-00455-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma
- (2020) Robert A. Figlin et al. CLINICAL CANCER RESEARCH
- Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.
- (2020) Cristina Masini et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting metabolic dysregulation of T cells in kidney cancer.
- (2020) Katy Beckermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
- (2020) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.
- (2020) Martin H Voss et al. JOURNAL OF CLINICAL ONCOLOGY
- The Emerging Landscape of Immune Cell Therapies
- (2020) Evan W. Weber et al. CELL
- Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
- (2020) Bradley A. McGregor et al. INVESTIGATIONAL NEW DRUGS
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
- (2020) Amod Sarnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
- (2020) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-8 and cancer prognosis on immunotherapy
- (2020) Ziad Bakouny et al. NATURE MEDICINE
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- (2020) Kobe C. Yuen et al. NATURE MEDICINE
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
- (2020) David A. Braun et al. NATURE MEDICINE
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
- (2020) Praful Ravi et al. JAMA Oncology
- Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
- (2020) Laure Hirsch et al. DRUGS
- Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
- (2020) Anita Gul et al. JOURNAL OF CLINICAL ONCOLOGY
- The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection
- (2020) Kristen E. Pauken et al. Cell Reports
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
- (2020) Robert J Motzer et al. Journal for ImmunoTherapy of Cancer
- Targeting the HIF2–VEGF axis in renal cell carcinoma
- (2020) Toni K. Choueiri et al. NATURE MEDICINE
- A Randomized Phase II Study of AGS‐16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma
- (2020) Christian Kollmannsberger et al. ONCOLOGIST
- A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma
- (2019) Sumanta K. Pal et al. CANCER
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
- (2019) Jean-Christophe Pignon et al. CLINICAL CANCER RESEARCH
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
- (2019) Patrick A. Ott et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- (2019) Vivek Verma et al. NATURE IMMUNOLOGY
- T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes
- (2019) Tomasz Kula et al. CELL
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
- (2019) Meredith M. Regan et al. JOURNAL OF CLINICAL ONCOLOGY
- CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models
- (2019) Huizhong Li et al. JOURNAL OF IMMUNOTHERAPY
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
- (2019) Henning Zelba et al. Cancer Immunology Research
- 910PDEfficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
- (2019) T K Choueiri et al. ANNALS OF ONCOLOGY
- 911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC
- (2019) E Jonasch et al. ANNALS OF ONCOLOGY
- 950PAssociation between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
- (2019) V Grünwald et al. ANNALS OF ONCOLOGY
- 971PTreatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma
- (2019) M M Regan et al. ANNALS OF ONCOLOGY
- 1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment
- (2019) D F McDermott et al. ANNALS OF ONCOLOGY
- 1202PPhase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
- (2019) N Mach et al. ANNALS OF ONCOLOGY
- 1224PPhase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours
- (2019) J Strauss et al. ANNALS OF ONCOLOGY
- 36P First CAR-T cell immunotherapy against HLA-G: Targeting a unique ICP and TAA
- (2019) M Loustau ANNALS OF ONCOLOGY
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
- (2019) David J. Clark et al. CELL
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
- (2019) Lawrence Fong et al. Cancer Discovery
- Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
- (2019) Katsiaryna Marhelava et al. Cancers
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- A large peptidome dataset improves HLA class I epitope prediction across most of the human population
- (2019) Siranush Sarkizova et al. NATURE BIOTECHNOLOGY
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas
- (2018) John A Thompson et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
- (2018) Kerry Reynolds et al. ONCOLOGIST
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
- (2018) Tao Wang et al. Cancer Discovery
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy
- (2018) Rikke Andersen et al. Cancer Immunology Research
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- Human endogenous retroviruses and their implication for immunotherapeutics of cancer
- (2018) A S Attermann et al. ANNALS OF ONCOLOGY
- A cloning and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens
- (2018) Zhuting Hu et al. BLOOD
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
- (2018) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- 1149PSafety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors
- (2018) A Spira et al. ANNALS OF ONCOLOGY
- Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
- (2018) Brian W. Labadie et al. CLINICAL CANCER RESEARCH
- Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
- (2018) Christof C. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma
- (2018) Rana R. McKay et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light
- (2018) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers
- (2018) Sabina Signoretti et al. JOURNAL OF CLINICAL ONCOLOGY
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Double-slit photoelectron interference in strong-field ionization of the neon dimer
- (2018) Maksim Kunitski et al. Nature Communications
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Targeting A2 adenosine receptors in cancer
- (2017) David Allard et al. IMMUNOLOGY AND CELL BIOLOGY
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
- (2017) Iulia Diaconu et al. MOLECULAR THERAPY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells
- (2017) Lei Song et al. Oncotarget
- Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
- (2017) Karim Chamie et al. JAMA Oncology
- Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
- (2016) B.S. Glisson et al. ANNALS OF ONCOLOGY
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview
- (2016) C. H. J. Lamers et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer
- (2016) Elena Cherkasova et al. CANCER RESEARCH
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
- (2016) Qiong J. Wang et al. CLINICAL CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma
- (2016) Constantijn H.J. Muselaers et al. EUROPEAN UROLOGY
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma
- (2015) Viktor Grünwald et al. EUROPEAN UROLOGY
- Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+T cells
- (2015) Theodoros Eleftheriadis et al. IMMUNOLOGY
- Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma
- (2015) Chen Cai et al. WORLD JOURNAL OF UROLOGY
- Human Tumor Antigens and Cancer Immunotherapy
- (2015) Nathalie Vigneron Biomed Research International
- The immunocytokine NHS-IL12 as a potential cancer therapeutic
- (2015) Jonathan Fallon et al. Oncotarget
- IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer
- (2015) Alexandra Kirner et al. Human Vaccines & Immunotherapeutics
- New insights into IL-12-mediated tumor suppression
- (2014) S Tugues et al. CELL DEATH AND DIFFERENTIATION
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
- (2014) David F. McDermott et al. CLINICAL CANCER RESEARCH
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy
- (2012) Asís Palazón et al. Cancer Discovery
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment
- (2010) Jacques Tostain et al. EUROPEAN JOURNAL OF CANCER
- Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells
- (2010) Roopali Gandhi et al. NATURE IMMUNOLOGY
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now